Intensive Care Medicine

, Volume 33, Issue 1, pp 137–142 | Cite as

Impact of antifungal treatment on CandidaPseudomonas interaction: a preliminary retrospective case–control study

  • Saad NseirEmail author
  • Elsa Jozefowicz
  • Béatrice Cavestri
  • Boualem Sendid
  • Christophe Di Pompeo
  • Florent Dewavrin
  • Raphaël Favory
  • Micheline Roussel-Delvallez
  • Alain Durocher
Brief Report



A pathogenic interaction between Candida albicans and Pseudomonas aeruginosa has recently been demonstrated. In addition, experimental and clinical studies identified Candida spp. tracheobronchial colonization as a risk factor for P. aeruginosa pneumonia. The aim of this study was to determine the impact of antifungal treatment on ventilator-associated pneumonia (VAP) or tracheobronchial colonization due to P. aeruginosa.

Design and setting

Retrospective observational case–control study conducted in a 30-bed ICU during a 1-year period.

Patients and methods

One hundred and two patients intubated and ventilated for longer than 48 h with tracheobronchial colonization by Candida spp. Routine screening for Candida spp. and P. aeruginosa was performed at ICU admission and weekly. Antifungal treatment was based on medical staff decisions. Patients with P. aeruginosa VAP or tracheobronchial colonization were matched (1:2) with patients without P. aeruginosa VAP or tracheobronchial colonization. In case and control patients, risk factors for P. aeruginosa VAP or tracheobronchial colonization were determined using univariate and multivariate analyses.


Thirty-six patients (35%) received antifungal treatment. Nineteen patients (18%) developed a P. aeruginosa VAP or tracheobronchial colonization, and all were successfully matched. Antifungal treatment [31% vs 60%; p = 0.037, OR (95% CI) = 0.67 (0.45–0.90)], and duration of antifungal treatment (7 ± 11 vs 14 ± 14 days; p = 0.045, in case and control patients respectively) were significantly associated with reduced risk for P. aeruginosa VAP or tracheobronchial colonization. Antifungal treatment was the only variable independently associated with P. aeruginosa VAP or tracheobronchial colonization (OR = 0.68, 95% CI = 0.49–0.90, p = 0.046).


In patients with Candida spp. tracheobronchial colonization, antifungal treatment may be associated with reduced risk for P. aeruginosa VAP or tracheobronchial colonization.


Pseudomonas aeruginosa Candida spp. Antifungal treatment Interaction Ventilator-associated pneumonia Tracheobronchial colonization 

Supplementary material

134_2006_422_MOESM1_ESM.doc (66 kb)
Electronic Supplementary Material (DOC 66K)


  1. 1.
    Safdar N, Dezfulian C, Collard HR, Saint S (2005) Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 33:2184–2193PubMedCrossRefGoogle Scholar
  2. 2.
    Sadikot RT, Blackwell TS, Christman JW, Prince AS (2005) Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 171:1209–1223PubMedCrossRefGoogle Scholar
  3. 3.
    Chastre J, Fagon JY (2002) Ventilator-associated pneumonia. Am J Respir Crit Care Med 165:867–903PubMedGoogle Scholar
  4. 4.
    Safdar N, Maki DG (2002) The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 136:834–844PubMedGoogle Scholar
  5. 5.
    Hogan DA, Kolter R (2002) PseudomonasCandida interactions: an ecological role for virulence factors. Science 296:2229–2232PubMedCrossRefGoogle Scholar
  6. 6.
    Hogan DA, Vik A, Kolter R (2004) A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol Microbiol 54:1212–1223PubMedCrossRefGoogle Scholar
  7. 7.
    Spinelli SL, Malik HS, Consaul SA, Phizicky EM (1998) A functional homolog of a yeast tRNA splicing enzyme is conserved in higher eukaryotes and in Escherichia coli. Proc Natl Acad Sci USA 95:14136–14141PubMedCrossRefGoogle Scholar
  8. 8.
    Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M, Zahar JR, Adrie C, Garrouste-Org M, Cohen Y, Mourvillier B, Schlemmer B (2006) Candida colonization of the respiratory tract and subsequent Pseudomonas ventilator-associated pneumonia. Chest 129:110–117PubMedCrossRefGoogle Scholar
  9. 9.
    Celum CL (2004) The interaction between herpes simplex virus and human immunodeficiency virus. Herpes 11 (Suppl 1):36A–45AGoogle Scholar
  10. 10.
    Seki M, Higashiyama Y, Tomono K, Yanagihara K, Ohno H, Kaneko Y, Izumikawa K, Miyazaki Y, Hirakata Y, Mizuta Y, Tashiro T, Kohno S (2004) Acute infection with influenza virus enhances susceptibility to fatal pneumonia following Streptococcus pneumoniae infection in mice with chronic pulmonary colonization with Pseudomonas aeruginosa. Clin Exp Immunol 137:35–40PubMedCrossRefGoogle Scholar
  11. 11.
    Neely AN, Law EJ, Holder IA (1986) Increased susceptibility to lethal Candida infections in burned mice preinfected with Pseudomonas aeruginosa or pretreated with proteolytic enzymes. Infect Immun 52:200–204PubMedGoogle Scholar
  12. 12.
    Roux D, Ricard JD, Dreyfuss D, De Prost N, Grossin M, Saumon G (2006) Impact de la colonisation des voies aériennes à Candida albicans sur l'émergence d'une pneumopathie à Pseudomonas aeruginosa chez le rat. Réanimation 15: S43 (abstract)CrossRefGoogle Scholar
  13. 13.
    Bauer TT, Torres A, Ferrer R, Heyer CM, Schultze-Werninghaus G, Rasche K (2002) Biofilm formation in endotracheal tubes. Association between pneumonia and the persistence of pathogens. Monaldi Arch Chest Dis 57:84–87PubMedGoogle Scholar
  14. 14.
    Adair CG, Gorman SP, Feron BM, Byers LM, Jones DS, Goldsmith CE, Moore JE, Kerr JR, Curran MD, Hogg G, Webb CH, McCarthy GJ, Milligan KR (1999) Implications of endotracheal tube biofilm for ventilator-associated pneumonia. Intensive Care Med 25:1072–1076PubMedCrossRefGoogle Scholar
  15. 15.
    Nseir S, Marquette CH (2003) Diagnosis of hospital-acquired pneumonia: postmortem studies. Infect Dis Clin North Am 17:707–716PubMedCrossRefGoogle Scholar
  16. 16.
    Azoulay E, Cohen Y, Zahar JR, Garrouste-Org M, Adrie C, Moine P, de Lassence A, Timsit JF (2004) Practices in non-neutropenic ICU patients with Candida-positive airway specimens. Intensive Care Med 30:1384–1389PubMedGoogle Scholar
  17. 17.
    Wood GC, Mueller EW, Croce MA, Boucher BA, Fabian TC (2006) Candida sp. isolated from bronchoalveolar lavage: clinical significance in critically ill trauma patients. Intensive Care Med 32:599–603PubMedCrossRefGoogle Scholar
  18. 18.
    Eggimann P, Garbino J, Pittet D (2003) Management of Candida species infections in critically ill patients. Lancet Infect Dis 3:772–785PubMedCrossRefGoogle Scholar
  19. 19.
    Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L, Boillot A (2004) Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 32:2443–2449PubMedCrossRefGoogle Scholar
  20. 20.
    Leon C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, Garnacho-Montero J, Leon MA (2006) A bedside scoring system (“Candida score”) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34:730–737PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Saad Nseir
    • 1
    • 2
    Email author
  • Elsa Jozefowicz
    • 1
  • Béatrice Cavestri
    • 1
  • Boualem Sendid
    • 3
  • Christophe Di Pompeo
    • 2
  • Florent Dewavrin
    • 1
  • Raphaël Favory
    • 1
  • Micheline Roussel-Delvallez
    • 4
  • Alain Durocher
    • 1
    • 2
  1. 1.Intensive Care Unit, Calmette HospitalUniversity Hospital of LilleLille cedexFrance
  2. 2.Medical Assessment LaboratoryLille II UniversityLilleFrance
  3. 3.Parasitology and Mycology Laboratory, Inserm U799, Calmette HospitalUniversity Hospital of LilleLille cedexFrance
  4. 4.Bacteriology Laboratory, Calmette HospitalUniversity Hospital of LilleLille cedexFrance

Personalised recommendations